Acute Leukemia, Leukemia
Conditions
Keywords
Leukemia, Acute Leukemia, Clinical Trial Diversity
Brief summary
The goal of this study is to test the feasibility of a data visualization tool called the Trial Enrollment Diversity Dashboard (TEDD) to ensure participant diversity in acute leukemia trial enrollment.
Detailed description
This study is about testing a tool called the Trial Enrollment Diversity Dashboard (TEDD) to see if it can help increase diversity in cancer clinical trials, specifically for leukemia. Clinical trials are important for developing new cancer treatments, but not all groups are equally represented in these trials. This can lead to treatments that may not work as well for everyone. The TEDD tool is designed to give medical professionals feedback on how diverse their patient enrollments are clinical trials. By using this tool, medical professionals can see if they are enrolling a diverse group of patients and make changes if needed. The study will involve a small group of medical professionals who treat leukemia patients. They will use the TEDD tool and provide feedback on its usability and effectiveness. Study procedures include completion of surveys and usage of the TEDD intervention dashboard. It is expected that about 12 medical professionals will take part in this research study. Participation in this research study is expected to last about 14 months. The National Cancer Institute is providing funding for this research study.
Interventions
BEHAVIORALTrial Enrollment Diversity Dashboard Behavioral
A data management and classification algorithm tool that provides personalized enrollment diversity performance data for clinician review and which aims to overcome race-ethnic disparities in Leukemia clinical trial participation. Data inputs and the Dashboard are within existing HIPAA-complaint electronic health records systems used at Dana-Farber Cancer Institute, and utilization data metrics are collected through the Tableau software supporting the intervention.
Sponsors
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
American Society of Clinical Oncology
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Medical Professionals: * Physician, nurse practitioner, or physician assistant -≥10% clinical effort (or one ½ day of clinic per week for those working \<1 FTE) * Treats adult patients with leukemia or related diseases at the study sites * Ability to understand and willingness to provide informed consent * Age 18 or older Inclusion Criteria Participant Population: * Age ≥18 years old * Diagnosis of leukemia, lymphoma, myeloma, or related diseases * Seen by a physician for this diagnosis at one of the study sites
Exclusion criteria
Medical Professionals: -Listed member of the research team
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| TEDD Utilization Rate | 12 months | Utilization will be measured as the proportion of quarters where a participant accessed the dashboard divided by the total number of study quarters. Based on 12 participants over 4 three-month quarters, there are a total of 48 person-quarters available for analysis. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORAndrew Hantel, MD
Dana-Farber Cancer Institute
Outcome results
None listed